Blau N, Bonafé L, Krägeloh-Mann I, Thöny B, Kierat L, Häusler M, Ramaekers V
Division of Clinical Chemistry and Biochemistry, University Children's Hospital, Zurich, Switzerland.
Neurology. 2003 Sep 9;61(5):642-7. doi: 10.1212/01.wnl.0000082726.08631.e7.
To describe three unrelated children with a distinctive variant of Aicardi-Goutières syndrome (AGS) characterized by microcephaly, severe mental and motor retardation, dyskinesia or spasticity, and occasional seizures.
Neuroimaging showed bilateral calcification of basal ganglia and white matter. CSF glucose, protein, cell count, and interferon alpha were normal. Abnormal CSF findings included extremely high neopterin (293 to 814 nmol/L; normal 12 to 30 nmol/L) and biopterin (226 to 416 nmol/L; normal 15 to 40 nmol/L) combined with lowered 5-methyltetrahydrofolate (23 to 48 nmol/L; normal 64 to 182 nmol/L) concentrations in two patients. The absence of pleocytosis and normal CSF interferon alpha was a characteristic finding compared to the classic AGS syndrome. Genetic and enzymatic tests excluded disorders of tetrahydrobiopterin metabolism, including mutation analysis of GTP cyclohydrolase feed-back regulatory protein. CSF investigations in three patients with classic AGS also showed increased pterins and partially lowered folate levels.
Intrathecal overproduction of pterins is the first biochemical abnormality identified in patients with AGS variants. Long-term substitution with folinic acid (2-4 mg/kg/day) resulted in substantial clinical recovery with normalization of CSF folates and pterins in one patient and clinical improvement in another. The underlying defect remains unknown.
描述三名患有Aicardi-Goutières综合征(AGS)独特变异型的不相关儿童,其特征为小头畸形、严重智力和运动发育迟缓、运动障碍或痉挛,以及偶尔发作的癫痫。
神经影像学显示双侧基底神经节和白质钙化。脑脊液葡萄糖、蛋白质、细胞计数和干扰素α水平正常。脑脊液异常表现包括两名患者的新蝶呤(293至814 nmol/L;正常为12至30 nmol/L)和生物蝶呤(226至416 nmol/L;正常为15至40 nmol/L)极高,同时5-甲基四氢叶酸浓度降低(23至48 nmol/L;正常为64至182 nmol/L)。与经典AGS综合征相比,无细胞增多且脑脊液干扰素α正常是其特征性表现。基因和酶学检测排除了四氢生物蝶呤代谢紊乱,包括GTP环水解酶反馈调节蛋白的突变分析。三名经典AGS患者的脑脊液检查也显示蝶呤增加且叶酸水平部分降低。
蝶呤的鞘内过度产生是在AGS变异型患者中发现的首个生化异常。一名患者长期使用亚叶酸(2 - 4 mg/kg/天)替代治疗后,脑脊液叶酸和蝶呤恢复正常,临床症状大幅改善,另一名患者临床症状也有所改善。潜在缺陷仍不明。